Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:57 PM
Ignite Modification Date:
2025-12-24 @ 10:57 PM
NCT ID:
NCT01200069
Eligibility Criteria:
Inclusion Criteria:
* Capable of providing informed consent
* American Society Anesthesiologists (ASA) rating I-III
* Subjects age 18-80 capable of providing consent.
* Subjects undergoing electroconvulsive therapy using succinylcholine as the sole neuromuscular blocking agent.
* Subjects who have scored ≥23 on the Mini-Mental State Examination.
Exclusion Criteria:
* Subjects who have had a recent thrombotic event, myocardial infarction or stroke or episode of Congestive Heart Failure (CHF) within less than 3 months.
* Subjects who have had a recent cardiovascular surgery within the last 3 months.
* Subjects with active Gastrointestinal bleeding
* Subjects who have asthma, itching or allergic type reaction following aspirin or other NSAID administration
* Subjects with a known hypersensitivity to ibuprofen
* Subjects with heart failure, bleeding disorders or kidney failure
* Subjects taking aspirin, Angiotensin converting enzyme (ACE) inhibitors, or anticoagulants within one month.
* Subjects with any devices used to treat pain (intrathecal pumps, spinal cord stimulators etc)
* Subjects with a history of fibromyalgia or chronic myositis
* Subjects who are pregnant
* Subjects who do not have a phone
* Subjects who have had previous ECT
* Subjects receiving toradol (Ketorolac)
* Subjects with reported renal disease within less than 3 months.
* Subjects who have had previous electroconvulsive therapy within the last 3 months
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT01200069
Study Brief:
Protocol Section:
NCT01200069